Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06479187 · ClinicalTrials.gov registry record · Phase 4

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

A Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer, sponsored by Brigham and Women's Hospital.

Active
Registry status
Phase 4
Development phase
20
Enrollment target
2
Study locations

NCT06479187 is a Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06479187, a Phase 4 study of Metastatic Prostate Cancer and Hormone Sensitive Prostate Cancer, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion of men with residual PSMA-avid disease on PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer? Do the findings on PSMA-PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer correlate with other markers of disease status, like PSA? Participants will: Receive standard of care treatment for metastatic hormone sensitive prostate cancer Undergo a PSMA-PET/CT scan before starting treatment Undergo a PSMA-PET/CT scan after 6 months of treatment Have a chart review every 3 months for 1 year after the 6 month PSMA-PET/CT scan

Conditions Studied

Metastatic Prostate Cancer Hormone Sensitive Prostate Cancer Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

  • DRUG 18F-rhPSMA-7.3
  • DEVICE PET/CT

Study Locations (2)

Massachusetts

  • Dana Farber Cancer Institute - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-06-30
Est. Completion 2027-06-20
Phase Phase 4

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06479187

The ClinicalTrials.gov registry entry for NCT06479187 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-rhPSMA-7.3 is the first listed.

NCT06479187 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06479187 about?

NCT06479187 is a clinical study titled "PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer". The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion o...

What is the current status of trial NCT06479187?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-06-30. Estimated completion is 2027-06-20.

What conditions does trial NCT06479187 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

What interventions are being tested in trial NCT06479187?

The interventions under investigation include: 18F-rhPSMA-7.3 (DRUG), PET/CT (DEVICE).

Who is sponsoring clinical trial NCT06479187?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06479187 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Prostate Cancer

All registered trials for this condition

Hormone Sensitive Prostate Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.